Acute Erythroblastic Leukemia News

Acute Erythroblastic Leukemia	Welcome, Profile Billing Logout

12 3 4 5 6 »

||||||||||  decitabine / Generic mfg.
Trial completion:  Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) -  Feb 19, 2019
P2, N=546, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) -  Jan 15, 2019
P2, N=11, Completed,  Sponsor: Rondeep Brar
Active, not recruiting --> Completed Recruiting --> Completed | N=33 --> 11 | Trial completion date: Dec 2019 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Dec 2017

||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
Phase classification, Enrollment change, Trial termination:  Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia (clinicaltrials.gov) -  Aug 23, 2018
P1, N=7, Terminated,  Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting --> Completed | N=33 --> 11 | Trial completion date: Dec 2019 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Dec 2017 Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply

||||||||||  NN1213 / Novo Nordisk
Trial completion:  Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (clinicaltrials.gov) -  Jul 11, 2018
P=N/A, N=16, Completed,  Sponsor: University of Washington
Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply Active, not recruiting --> Completed

||||||||||  fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion, Enrollment change:  Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov) -  Jun 12, 2018
P2, N=121, Completed,  Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=61 --> 121

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Trial completion, Enrollment change:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 3, 2018
P=N/A, N=48, Completed,  Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | N=61 --> 121 Active, not recruiting --> Completed | N=90 --> 48

|||||||||| Enrollment change, Trial termination: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 1, 2018
P1, N=17, Terminated, Sponsor: Stanford University
Active, not recruiting --> Completed | N=90 --> 48 N=30 --> 17 | Recruiting --> Terminated; Accrual factor

||||||||||  Zarnestra (tipifarnib) / Kura Oncology
Trial completion:  Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission (clinicaltrials.gov) -  Apr 19, 2018
P3, N=144, Completed,  Sponsor: National Cancer Institute (NCI)
N=30 --> 17 | Recruiting --> Terminated; Accrual factor Active, not recruiting --> Completed

||||||||||  Mekinist (trametinib) / Novartis, BeiGene, uprosertib (LAE003) / Laekna Therap
Trial termination, Combination therapy:  Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Apr 6, 2018
P2, N=24, Terminated,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Lack of efficacy.

|||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 31, 2018
P1, N=10, Terminated, Sponsor: University of Southern California
Active, not recruiting --> Terminated; Lack of efficacy. N=35 --> 10 | Trial completion date: Mar 2019 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Jul 2017; Insufficient Accrual

||||||||||  mitoxantrone / Generic mfg., gemcitabine / Generic mfg.
Trial termination:  Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) -  Feb 22, 2018
P2, N=24, Terminated,  Sponsor: The Cleveland Clinic
Completed --> Terminated; If </= 5 of the initial 18 patients had a CR, the study would be stopped. Only 5 patients (21%) of 24 enrolled patients had a CR so the study was terminated.

|||||||||| Trial completion, Trial primary completion date: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Jan 12, 2018
P1/2, N=52, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Only 5 patients (21%) of 24 enrolled patients had a CR so the study was terminated. Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Aug 2016

|||||||||| Trial primary completion date: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 11, 2018
P1, N=30, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Aug 2016 Trial primary completion date: Dec 2017 --> Dec 2018

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Trial completion, Trial primary completion date:  S1203: Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) -  Dec 8, 2017
P3, N=756, Completed,  Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Jun 2017

||||||||||  Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment change, Trial termination, Trial primary completion date:  MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Dec 5, 2017
P1, N=1, Terminated,  Sponsor: Bruno C. Medeiros
Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Jun 2017 N=19 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2015; logistics

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial primary completion date:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 19, 2017
P=N/A, N=90, Active, not recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
N=19 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2015; logistics Trial primary completion date: Jun 2017 --> Jan 2017

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Enrollment open, Trial primary completion date:  CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) -  Jun 14, 2017
P2, N=33, Recruiting,  Sponsor: Bruno C. Medeiros
Trial primary completion date: Jun 2017 --> Jan 2017 Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2017 --> Jul 2019

|||||||||| Enrollment open: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 14, 2017
P1, N=30, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2017 --> Jul 2019 Active, not recruiting --> Recruiting

||||||||||  Zolinza (vorinostat) / Merck (MSD), Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment change, Combination therapy:  Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 1, 2017
P2, N=31, Terminated,  Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Recruiting N=107 --> 31

|||||||||| Trial completion: Studying Tissue Samples to Learn More About Drug Resistance in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2017
P=N/A, N=40, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
N=107 --> 31 Not yet recruiting --> Completed

|||||||||| Biomarker, Trial completion, Adverse events: Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 17, 2017
P=N/A, N=257, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Completed Not yet recruiting --> Completed

|||||||||| Biomarker, Trial completion, Trial initiation date, Trial primary completion date: Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 17, 2017
P=N/A, N=220, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Completed Not yet recruiting --> Completed | Initiation date: Aug 2011 --> Jan 2012 | Trial primary completion date: Sep 2011 --> Feb 2012

|||||||||| Biomarker, Trial completion, Trial initiation date, Trial primary completion date: Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 17, 2017
P=N/A, N=30, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Not yet recruiting --> Completed | Initiation date: Aug 2011 --> Jan 2012 | Trial primary completion date: Sep 2011 --> Feb 2012 Not yet recruiting --> Completed | Initiation date: Sep 2010 --> May 2009 | Trial primary completion date: Oct 2010 --> Jun 2009

||||||||||  cytarabine / Generic mfg.
Biomarker, Trial completion, Trial initiation date, Trial primary completion date:  Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy (clinicaltrials.gov) -  May 17, 2017
P=N/A, N=200, Completed,  Sponsor: ECOG-ACRIN Cancer Research Group
Not yet recruiting --> Completed | Initiation date: Sep 2010 --> May 2009 | Trial primary completion date: Oct 2010 --> Jun 2009 Not yet recruiting --> Completed | Initiation date: Oct 2009 --> Jul 2010 | Trial primary completion date: Nov 2009 --> Aug 2010

||||||||||  lithium carbonate ER / Generic mfg.
Trial completion, Enrollment change:  Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Apr 27, 2017
P1, N=12, Completed,  Sponsor: Paolo Caimi, MD
Not yet recruiting --> Completed | Initiation date: Oct 2009 --> Jul 2010 | Trial primary completion date: Nov 2009 --> Aug 2010 Active, not recruiting --> Completed | N=24 --> 12

|||||||||| Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 20, 2017
P1, N=35, Recruiting, Sponsor: University of Southern California
Active, not recruiting --> Completed | N=24 --> 12 Trial primary completion date: Mar 2016 --> Mar 2018

||||||||||  cytarabine / Generic mfg., clofarabine / Generic mfg.
Trial completion, Trial primary completion date:  Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Apr 19, 2017
P1, N=53, Completed,  Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Mar 2016 --> Mar 2018 Active, not recruiting --> Completed | Trial primary completion date: Nov 2008 --> Jan 2015

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment change:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Mar 31, 2017
P=N/A, N=90, Active, not recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | Trial primary completion date: Nov 2008 --> Jan 2015 N=46 --> 90

|||||||||| Trial primary completion date: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 15, 2017
P1, N=30, Active, not recruiting, Sponsor: Stanford University
N=46 --> 90 Trial primary completion date: Feb 2017 --> Dec 2017

||||||||||  fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date:  Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov) -  Feb 23, 2017
P2, N=61, Active, not recruiting,  Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Feb 2017 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2013

|||||||||| Trial primary completion date: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Jan 31, 2017
P1/2, N=50, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2016 --> Dec 2013 Trial primary completion date: Dec 2016 --> Dec 2017

||||||||||  Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date:  MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 30, 2017
P1, N=19, Active, not recruiting,  Sponsor: Bruno C. Medeiros
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2019

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment closed, Enrollment change:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 12, 2017
P=N/A, N=46, Active, not recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2016 --> Dec 2019 Recruiting --> Active, not recruiting | N=90 --> 46

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial primary completion date:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Oct 26, 2016
P=N/A, N=90, Recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting | N=90 --> 46 Trial primary completion date: Dec 2016 --> Jun 2017

||||||||||  arsenic trioxide / Generic mfg.
Enrollment change, Trial withdrawal:  Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Oct 5, 2016
P2, N=0, Withdrawn,  Sponsor: Stanford University
Trial primary completion date: Dec 2016 --> Jun 2017 N=16 --> 0 | Not yet recruiting --> Withdrawn

||||||||||  Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion:  RAEB-t: Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) -  Sep 20, 2016
P3, N=600, Completed,  Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
N=16 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed

||||||||||  metformin / Generic mfg., cytarabine / Generic mfg.
Trial primary completion date:  Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (clinicaltrials.gov) -  Sep 2, 2016
P1, N=2, Active, not recruiting,  Sponsor: Northwestern University
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Jul 2018

|||||||||| Enrollment closed: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Aug 10, 2016
P1/2, N=50, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jul 2016 --> Jul 2018 Recruiting --> Active, not recruiting

||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial completion:  Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission (clinicaltrials.gov) -  Jun 26, 2016
P2, N=51, Completed,  Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  Mekinist (trametinib) / Novartis, BeiGene, uprosertib (LAE003) / Laekna Therap
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy:  Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Jun 5, 2016
P2, N=20, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=45 --> 20 | Trial primary completion date: May 2016 --> Jan 2016

||||||||||  Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Biomarker, Trial completion, Trial primary completion date:  Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531 (clinicaltrials.gov) -  May 19, 2016
P=N/A, N=1000, Completed,  Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting | N=45 --> 20 | Trial primary completion date: May 2016 --> Jan 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016

|||||||||| Biomarker, Trial completion, Trial primary completion date: Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=234, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016

|||||||||| Biomarker, Trial completion, Trial primary completion date: Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=250, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016

|||||||||| Trial primary completion date: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - May 19, 2016
P1/2, N=52, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Trial primary completion date: Jun 2016 --> Dec 2016

|||||||||| Trial completion, Trial primary completion date: Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=98, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Jun 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016

|||||||||| Biomarker, Trial completion, Trial primary completion date: Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=97, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016

|||||||||| Trial completion, Trial initiation date, Trial primary completion date: Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Initiation date: Oct 2009 --> May 2009 | Trial primary completion date: Jan 2100 --> May 2016

||||||||||  Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial primary completion date:  Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Apr 28, 2016
P=N/A, N=90, Recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed | Initiation date: Oct 2009 --> May 2009 | Trial primary completion date: Jan 2100 --> May 2016 Trial primary completion date: Jun 2016 --> Dec 2016

|||||||||| Enrollment closed: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 27, 2016
P1, N=30, Active, not recruiting, Sponsor: Stanford University
Trial primary completion date: Jun 2016 --> Dec 2016 Suspended --> Active, not recruiting

||||||||||  Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment closed:  MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Apr 27, 2016
P1, N=19, Active, not recruiting,  Sponsor: Bruno C. Medeiros
Suspended --> Active, not recruiting Suspended --> Active, not recruiting



	Diseases Companies Products Productz Mechanisms of Action Sites